Insider Transactions in Q3 2025 at Monopar Therapeutics (MNPR)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 24
2025
|
Tactic Pharma LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
550,229
-66.92%
|
$34,664,427
$63.61 P/Share
|
|
Jul 14
2025
|
Kim R Tsuchimoto Director |
SELL
Open market or private sale
|
Direct |
8,904
-43.67%
|
$356,160
$40.0 P/Share
|
|
Jul 14
2025
|
Kim R Tsuchimoto Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
8,904
+30.4%
|
-
|
|
Jul 14
2025
|
Chandler Robinson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,800
-18.61%
|
$672,000
$40.0 P/Share
|
|
Jul 14
2025
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
16,800
+15.69%
|
-
|
|
Jul 14
2025
|
Christopher M Starr Director |
SELL
Open market or private sale
|
Direct |
16,800
-76.46%
|
$672,000
$40.0 P/Share
|
|
Jul 14
2025
|
Christopher M Starr Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
16,800
+43.33%
|
-
|